ETrade Capital Management’s United Therapeutics UTHR Stock Holding History

ETrade Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,666	Closed	-$202K	–	940
2020 Q2	$202K	Buy	+1,666	New	+$187K	﹤0.01%	786
2019 Q2	–	Sell	-2,199	Closed	-$258K	–	835
2019 Q1	$258K	Sell	2,199 -2,774	-56%	-$323K	0.01%	712
2018 Q4	$542K	Buy	4,973 +1,112	+29%	+$129K	0.02%	467
2018 Q3	$494K	Buy	3,861 +274	+8%	+$33.9K	0.01%	556
2018 Q2	$406K	Buy	3,587 +215	+6%	+$23.6K	0.01%	572
2018 Q1	$379K	Buy	3,372 +435	+15%	+$55.3K	0.01%	571
2017 Q4	$435K	Buy	2,937 +465	+19%	+$59.1K	0.01%	539
2017 Q3	$290K	Buy	2,472 +311	+14%	+$39.7K	0.01%	587
2017 Q2	$280K	Buy	2,161 +527	+32%	+$65.7K	0.01%	584
2017 Q1	$221K	Buy	+1,634	New	+$248K	0.01%	596
2014 Q1	–	Sell	-883	Closed	-$100K	–	876
2013 Q4	$100K	Buy	883 +60	+7%	+$5.41K	0.01%	370
2013 Q3	$65K	Buy	823 +561	+214%	+$41K	0.01%	399
2013 Q2	$17K	Buy	+262	New	+$16.9K	﹤0.01%	515

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

ETrade Capital Management's UTHR Position: Q3 2020 in Review

ETrade Capital Management sold out of United Therapeutics (UTHR) in Q3 2020, closing a stake of 1,666 shares — an estimated $202K sold.

ETrade Capital Management first reported a position in UTHR in Q2 2013 and held it in 13 quarters. The position peaked at $542K in Q4 2018. 333 funds tracked by Wall St. Rank hold UTHR as of Q3 2020.

ETrade Capital Management reported no remaining United Therapeutics position as of Q3 2020 after selling out during the quarter.
ETrade Capital Management sold 1,666 United Therapeutics shares in Q3 2020, an estimated $202K.
ETrade Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 13 quarters.
ETrade Capital Management's United Therapeutics position peaked at $542K in Q4 2018.
333 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.